Captain T Cell, a Berlin-Schönefeld-based biotech company, is pioneering next-generation TCR-T therapies for solid tumor patients that are in urgent need for novel treatment options. The company’s best-in-class autologous lead candidate will enter the clinic in 2027 in a first-in-human, multicenter Phase I trial led by Charité – Universitätsmedizin and supported by eight leading German university hospitals. In parallel, Captain T Cell is building a first-in-class TCR-ALLO platform, which has reached preclinical proof of concept.
Spun out in 2024 from the Max Delbrück Center, Berlin, Germany – a renowned European biomedical research institution – and supported by a strong seed round consortium of life-science-specialized venture capital firms, Captain T Cell aims to overcome the core challenges of cell-based immunotherapies including durability, manufacturing and scalability.
